Attitudes toward molecular testing for personalized cancer therapy

By Yusuf Rafeek A.   Rogith Deevakar   Hovick Shelly R. A.   Peterson Susan K.   Burton-Chase Allison M.   Fellman Bryan M.   Li Yisheng   McKinney Carolyn   Bernstam Elmer V.   Meric-Bernstam Funda  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 243-250

Blackwell Publishing

Access to resources Recommend Favorite

Bladder Cancer: Molecular Determinants of Personalized Therapy

By  

Current Drug Targets, Vol. 16, Iss. 2, 2015-02 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Therapy Intervention Prospects in Prostate Cancer

By  

Current Pharmaceutical Design, Vol. 10, Iss. 5, 2004-02 ,pp. : 523-530

Bentham Science Publishers

Access to resources Recommend Favorite

Par-4 for Molecular Therapy of Prostate Cancer

By  

Current Drug Targets, Vol. 4, Iss. 3, 2003-04 ,pp. : 223-230

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer

By  

Current Drug Targets, Vol. 19, Iss. 15, 2018-12 ,pp. : 1731-1737

Bentham Science Publishers

Access to resources Recommend Favorite